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Summary 
 Hypoxia-inducible factor 1 (HIF-1) plays essential roles in tumor angiogenesis and growth by 
regulating the transcription of several key genes in response to hypoxic stress and growth 
factors. HIF-1 is a heterodimeric transcriptional activator consisting of inducible α  and 
constitutive β  subunits. In oxygenated cells, proteins containing the prolyl hydroxylase 
domain（PHD） directly sense intracellular oxygen concentrations. PHDs tag HIF-1αsubunits 
for polyubiquitination and proteasomal degradation by prolyl hydroxylation using 
2-oxoglutarate（2-OX） and dioxygen. Our recent studies showed that 2-OX reduces HIF-1α, 
erythropoietin and vascular endothelial growth factor (VEGF) expression in the hepatoma cell 
line Hep3B when under hypoxic conditions in vitro. Here, we report that similar results were 
obtained in Lewis lung cancer（LLC）cells in in vitro studies. Furthermore, 2-OX showed potent 
anti-tumor effects in a mouse dorsal air sac (DAS) assay and a murine tumor xenograft model. 
In the DAS assay, 2-OX reduced the numbers of newly formed vessels induced by LLC cells. In 
a murine tumor xenograft model, intraperitoneal injection of 2-OX significantly inhibited tumor 
growth and angiogenesis in tumor tissues. Moreover, 5-fluorouracil combined with 2-OX 
significantly inhibited tumor growth in this model, which was accompanied by reduction of 
Vegf gene expression in tumor tissues. These results suggest that 2-OX is a promising 
anti-angiogenic therapeutic agent.  
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Introduction 
   The growth of solid tumors is frequently accompanied by neovascularization. This 
requirement for angiogenesis implied that targeting tumor vascular endothelial cells might 
represent a novel therapeutic strategy (1). Proof of principle was established through clinical 
applications demonstrating efficacy of the anti-vascular endothelial growth factor（VEGF）
antibody, bevacizumab (2) . 
   VEGF is a potent angiogenic factor and endothelial cell-specific mitogen(3, 4, 5) that is 
regulated by hypoxia in vitro(6)  and in vivo (7, 8, 9, 10). This hypoxic induction of VEGF is due to 
an increase in the steady state level of Vegf mRNA (11). Similar to the erythropoietin (Epo) 
gene(6), the Vegf gene is induced by metal ions and hypoxia(10). The implication of these studies 
is that there may be fundamental similarities in the oxygen-sensing pathway leading to the 
activation of these two genes. Hypoxic induction of the Epo gene appears to be regulated by 
both transcriptional and post-transcriptional mechanisms(12, 13, 14). Hypoxia-inducible factor 1 
(HIF-1) was identified as a protein that specifically binds to an enhancer element 3’ to the Epo 
gene in a hypoxia-regulated fashion (15, 16). 
   HIF-1 is a key regulator of responses to hypoxia, occupying a central position in oxygen 
homeostasis in a wide range of organisms(17). Among its transcriptional targets are genes with 
critical roles in angiogenesis, erythropoiesis, energy metabolism, vasomotor function, and 
apoptotic/proliferative responses. HIF-1 is also essential for normal development(18) and plays 
key roles in pathophysiological responses to ischemia/hypoxia as well as in tumor growth and 
angiogenesis(17).  
   HIF-1 is a heterodimeric transcription factor composed of a HIF-1α subunit and a HIF-1β 
subunit(19). HIF-1α is continuously synthesized and degraded under normoxic conditions. 
 5 
Under hypoxic conditions, HIF-1α  degradation is inhibited, allowing the protein to 
accumulate and dimerize with HIF-1β. This heterodimer binds to cis-acting hypoxia-response 
elements in target genes and recruits coactivator proteins, all of which leads to increased 
transcription. In oxygenated cells, intracellular oxygen concentrations are directly sensed by 
HIF-1αhydroxylation enzymes, prolyl hydroxylases（PHDs）. PHDs tag HIF-1α subunits for 
polyubiquitination and proteasomal degradation by prolyl hydroxylation using 2-oxoglutarate
（2-OX） and dioxygen(20, 21).  Our recent studies have shown that 2-OX reduces HIF-1α, 
erythropoietin, and VEGF expression under hypoxic conditions in the hepatoma cell line 
Hep3B(22). To address the clinical usefulness of 2-OX, we investigated its anti-tumor effect 
using a mouse dorsal air sac (DAS) assay and a murine tumor xenograft model. We found that 
2-OX exerts potent anti-tumor effects by inhibiting angiogenesis, and we discuss the possibility 
of 2-OX as a novel anti-angiogenesis drug. 
 
Material and Methods 
 
Cell culture. The Lewis lung carcinoma（LLC）and B16F10 melanoma cell lines were obtained 
from the American Type Tissue Culture Collection (Rockville, MD, USA). Cells were incubated 
under both 21% (normoxia) and 1% (hypoxia) oxygen. The exposure times were as described 
below.    
Cell proliferation assay. Cell survival was determined by a nonradioactive cell proliferation 
assay (Promega, WI, USA). LLC cells (1.5×104 cells) in a 96-well plate (Nunc A/S, Roskilde, 
Denmark) were incubated for 24 h. Then the medium was changed to new medium containing 
various concentrations of 2-OX (Fluka, Buchs, Switzerland) and incubated under normoxic 
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(21% O2) or hypoxic (1% O2) conditions for 20h. After incubation, the tetrazolium component 
of the Dye Solution was added. After incubation for 4 h, the Solubilization/Stop Solution was 
added to the cultures to solubilize the formazan product, and the absorbance reading at 570 nm 
was recorded by a 96-well plate reader (Bio-Rad, CA, USA). 
Semi-quantitative RT-PCR. We used the following primers for RT-PCR: HIF-1α-sense, 
5’-GAGTTCTGAACGTCGAAAAG-3’; HIF-1 α -antisense, 
5’-CTCACACGTAAATAACTGATGG-3’;  HIF-2 α -sense, 
5’-GGACGCTCTGCCTATGAGTT-3’; HIF-2α-antisense, 
5’-GGCTCCTCCTTCAGTTTGG-3’;β-actin-sense, 5’-GTGCTATGTTGCCCTGGATT-3’;β
-actin antisense, 5’-TGCTAGGGCTGTGATCTCCT-3’. We extracted RNA using the RNeasy 
kit（Qiagen）. Total RNA（1μg） was primed with 0.5 μg of oligo dT and reverse transcribed 
by Omniscript reverse transcriptase using a primeScript RT-PCR kit (Takara). PCR proceeded 
using the cDNA as a template and TakaRa EX TaqTM HS（Takara）. The number of PCR cycles 
determined from the plot was thirty for both HIF-1α and HIF-2α and 25 for β-actin. 
Western blot analysis. Nuclear extracts (15 µg) prepared from LLC cells were electrophoresed 
on a 7.5% sodium dodecyl sulfate (SDS)-polyacrylamide gel and transferred onto a 
polyvinylidene difluoride membrane (Millipore, Billerica, MA, USA). Blocking was performed at 
room temperature for 1 h in phosphate-buffered saline (PBS) containing 5% nonfat milk. The 
membranes were incubated with anti-HIF-1α antibody (Lab vision, Fremont, CA, USA) in PBS 
containing 5% nonfat milk. After washing with PBS containing 0.1% Tween 20, the membrane 
was incubated with horseradish peroxidase-conjugated goat anti-mouse IgG (Zymed, San 
Francisco, CA, USA) in PBS containing 5% nonfat milk. Subsequently, proteins were detected by 
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enhanced chemiluminescence (Millipore). Goat anti-lamin B antibody (Santa Cruz Biotechnology, 
Santa Cruz , CA, USA) was used to monitor protein loading and transfer efficiency. 
Quantitative RT-PCR. We extracted RNA using the RNeasy kit（Qiagen）. Total RNA（1μg） 
was primed with 0.5 μg of oligo dT and reverse transcribed by Omniscript reverse transcriptase 
using a PrimeScript RT-PCR kit (Takara). The reaction was performed at 42°C for 30 min. The 
mRNA expression levels were analyzed by real-time quantitative PCR with TaqMan probe 
using an applied Biosystems 7500 Real-time PCR system (Perkin-Elmer Applied Biosystems, 
Foster, CA, USA) as previously described. The expression of Actin mRNA was used as an 
internal control. The PCR mixture (25μL total volume) consisted of FAM-labeled primer 
probes (Roche Diagnostics GmbH, Mannheim, Germany) and FastStart Universal Probe Master 
[ROX] (Roche Diagnostics GmbH). Each PCR amplification was performed in triplicate, using 
the following profile: one cycle of 95°C for 10min, 40 cycles of 94°C for 15 s, and 60°C for 1 
min. The quantitative values of target mRNA were normalized to that of actin mRNA 
expression. 
ELISA. To determine the levels of VEGF protein from the LLC cells, commercial 
enzyme-linked immunosorbent assays (ELISA: mouse VEGF; R&D systems, Minneapolis, 
MN) were used. ELISA was performed following the recommendations of the manufacturer. 
The detection limits is 3 pg/mL for VEGF. 
Mice. Seven-week-old male C57BL/6J mice were purchased from Clea-Japan (Tokyo, Japan). 
They were housed in autocleaning metal cages in an air-conditioned room and were offered a 
standard diet (CM; Oriental Yeast, Tokyo, Japan) and tap water ad libitum. This study was 
approved in accordance with the Regulations for Animal Experimentation at the University of 
Tsukuba and the Law on Human Treatment and Management of Animals (Law No. 105 of 
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Japan). 
Mouse Dorsal Air Sac (DAS) Assay. Tumor-induced blood vessel formation was assessed as 
described previously （23）. In brief, Millipore chambers (Millipore) were filled with either PBS 
alone or a suspension of 1.5 x 107 LLC cells in PBS with or without 2-OX and sealed with 
membrane filters (0.45 µm pores). Chambers were implanted subcutaneously in dorsal air sacs 
created surgically by injection of an appropriate volume of air in seven-week-old male 
C57BL/6J mice. Four days later, mice were given an overdose of diethyl ether. The skin was 
carefully removed and angiogenesis that had been induced around the chamber was examined 
under a stereomicroscope and photographed. Quantitative analyses were performed with 
angiogenesis-measuring software (version 2.0; Kurabo, Osaka, Japan). Each experimental group 
included four mice, and each experiment was repeated at least twice. No obvious adverse effects 
appeared after treatment of animals with 2-OX. All surgical procedures were performed under 
pentobarbital anesthesia (Dainabot, Osaka, Japan).   
Effect of 2-OX on growth of LLC cells in vivo. Cells in PBS were implanted into the right 
flank region of seven-week-old C57BL/6J mice. Daily intraperitoneal injections of 2-OX were 
started the day after implantation. From six to twelve days after implantation, we measured 
tumors with calipers and calculated volumes as (length x width2) x 0.5. LLC tumors were 
removed from mice twelve days after implantation for quantitative RT-PCR and 
immunohistochemical studies. 
Effect of 2-OX and/or 5-fluorouracil（5-FU）on growth of LLC cells in vivo. Cells in PBS 
were implanted into the right flank region of seven-week-old C57BL/6J mice. Mice were 
randomly assigned to four groups: (1) PBS alone, (2) 2-OX alone, (3) 5-FU alone, and (4) 5-FU
＋2-OX. For all groups, 5-FU was injected intraperitoneally on day 7 and 2-OX was injected 
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intraperitoneally daily from day 7-15. From six to fifteen days after implantation, we measured 
tumors with calipers and calculated volumes as (length x width2) x 0.5. LLC tumors were 
removed from mice fifteen days after implantation for quantitative RT-PCR. 
Immunohistochemistry and vessel density determination. Tumors were fixed overnight in 
4% paraformaldehyde in PBS. Half of the tumor was frozen, and cryosectioning was carried out 
at a thickness of 5μm for immunohistochemical staining. Briefly, all tissue sections were 
permeabilized with 0.1% Triton X-100 (Sigma, St Louis, MO, USA), blocked with goat normal 
serum for 30min for nonspecific binding, and then incubated with a rat monoclonal antibody 
against mouse CD31 (Pharmingen BD, Stockholm, Sweden) overnight at 4°C. Primary 
antibodies were detected with secondary chicken anti-rat IgG conjugated to Alexa 488 
(Molecular Probes Inc., Eugene, OR, USA) for immunofluorescence detection and nuclei were 
counterstained with 4,6-diamidino-2-phenylindole (DAPI). Quantitative analyses were 
performed with angiogenesis-measuring software (Kurabo). 
Statistical analysis. Student’s t tests were used to assess the level of significance between the 
treatment groups. 
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Results 
  2-OX reduces HIF-1α  protein level in cultured LLC cells. Our previous studies showed 
that 2-OX reduces HIF-1α, Epo and VEGF expression in a hepatoma cell line Hep3B when 
grown under hypoxic conditions. This implies that 2-OX may be able to reduce tumor growth 
by inhibition of HIF-1 activity in the tumor because VEGF induction by hypoxia is responsible 
for tumor growth and angiogenesis. In order to evaluate the effect of 2-OX on LLC tumor 
growth in an animal model, we first investigated the cytotoxic effect of 2-OX on LLC tumor 
cells. Cell cytotoxicity was determined by a cell proliferation assay following the addition of 
2-OX to LLC cells. There was no cell cytotoxicity up to 15 mM 2-OX (Fig.1A). LLC cells 
express HIF-1α mRNA, but not HIF-2α mRNA（Fig. 1B）. To elucidate the effect of 2-OX 
on the production of HIF-1α protein in LLC cells, western blot analysis was performed. 
Compared with normoxia, hypoxia markedly induced the expression level of HIF-1α protein 
(Fig. 1C, upper panel, lane 2). However, the addition of 7.5 and 15 mM 2-OX dose-dependently 
reduced HIF-1α protein production (Fig. 1C, upper panel), although the addition of 2-OX did 
not affect lamin B, which was used as a control (Fig.2B, lower panel). These results suggest that 
2-OX reduces the HIF-1α protein level.  
   2-OX reduces Vegf mRNA and protein levels in cultured LLC cells. Vegf mRNA 
expression induced by 1.5 hr hypoxic treatment in LLC cells was 1.65 ± 0.12-fold times that of 
the normoxic control（Fig.2A）. To elucidate the dose-dependent effects of 2-OX on Vegf mRNA 
expression in LLC cells, different concentrations of 2-OX were added to the cultures. Addition 
of 7.5 and 15 mM 2-OX decreased Vegf mRNA expression to 1.47 ± 0.12 and 1.29 ± 0.14 times 
that of the normoxic control, respectively（Fig.2A）. Vegf mRNA expression in LLC cells 
induced by 3 hr hypoxia treatment was 3.70 ± 0.55-fold times that of the normoxic control
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（Fig.2A）. Addition of 7.5 and 15 mM 2-OX reduced the Vegf mRNA level to 3.32 ± 0.26 and 
1.97 ± 0.27 times that of the normoxic control, respectively（Fig.2A）. These results indicate that 
2-OX inhibits Vegf mRNA expression in LLC cells in a dose-dependent manner.  
   To evaluate the VEGF protein levels after 2-OX treatment, an ELISA assay was performed. 
Hypoxia-induced VEGF protein production from LLC cells was 289.3 ± 25.6 pg/mg protein 
(Fig.2B). To elucidate the dose-dependent effects of 2-OX on the production of VEGF by LLC 
cells, different concentrations of 2-OX were added to the cultures. Addition of 7.5 or 15 mM 
2-OX inhibited VEGF protein production to 253.5 ± 17.8 and 178.6 ± 23.7 pg/mg protein, 
respectively (Fig.2B). These results indicate that 2-OX inhibits VEGF protein production by 
LLC cells in a dose-dependent manner. Thus, consistent with the reduction of VEGF mRNA, 
VEGF protein is reduced by 2-OX treatment in a dose-dependent manner in LLC cells. 
   2-OX inhibits blood vessel formation in vivo. To assess the effect of 2-OX on tumor 
angiogenesis in vivo, we performed DAS assays using LLC cells. When mice were implanted 
with a chamber that carried LLC cells, blood vessels characterized by strikingly disorganized 
and tortuous vessels were induced towards the chamber from pre-existing blood vessels beneath 
the epidermis (Fig.3A). Such tumor-induced blood vessel formation was, however, reduced by 
the administration of 2-OX (Fig.3A). Quantitative analysis of the values of blood vessel area by 
LLC cells using angiogenesis-measuring software were as follows: LLC only, 100 ± 20.8%; 
LLC+7.5mM 2-OX, 64.0 ± 9.4%; and LLC+15mM 2-OX, 45.6 ± 4.4%（Fig.3A）. In contrast, 
2-OX had little influence on the pre-existing blood vessels under the chamber（Fig.3B）. In this 
model, 2-OX showed significant dose-dependent anti-angiogenic effects, reducing the number 
of newly formed vessels induced by LLC cells. This result indicates that 2-OX clearly inhibited 
the angiogenesis induced by LLC cells in a dose-dependent manner. 
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   2-OX inhibits tumor growth and angiogenesis in vivo. To assess the effect of 2-OX on 
tumor growth, we injected 2-OX into mice with solid tumors. Tumor volumes and weights 
twelve days after implantation were as follows: PBS alone, 330.8 ± 108.1 mm3 and 192.6 ± 66.4 
mg; 50mg/kg 2-OX, 128.8 ± 16.4 mm3 and 111.0 ± 64.5 mg; and 100mg/kg 2-OX, 78.7 ± 43.7 
mm3 and 88.8 ± 57.5 mg（Fig.4A, B, C）. These data indicate that 2-OX reduces tumor size.  
We observed significant differences in microvessel density（PBS alone, 100 ± 16.5 %; and 
100mg/kg 2-OX, 46.0 ± 13.5 %）by immunostaining for the endothelial cell marker CD31
（Fig.5A, B）. 2-OX treatment（100mg/kg） tended to decrease the expression level of the Vegf 
gene in tumor tissues compared with the control by quantitative RT-PCR（Fig.5C）. In this 
xenograft model, intraperitoneal injection of 2-OX significantly inhibited tumor growth and 
angiogenesis in tumor tissues. We observed that topical 2-OX treatment reduced tumor growth 
in C57BL/6J mice bearing LLC tumors（data not shown）. 
   2-OX in combination with 5-FU chemotherapy clearly inhibited tumor growth and 
tissue Vegf expression in vivo. Anti-VEGF antibody bevacizumab has been used clinically to 
reduce tumor growth in combination with chemotherapeutic reagents such as 5-FU（25）. To assess 
the effect of 2-OX in combination with 5-FU on tumor growth, we injected 2-OX and 5-FU 
intraperitoneally in mice with solid tumors. Tumor volumes and weights fifteen days after 
implantation were as follows: PBS alone, 531.2 ± 144.9 mm3 and 306.3 ± 186.6 mg; 2-OX 
alone, 324.0 ± 156.5 mm3 and 308.7 ± 299.0 mg; 5-FU alone, 287.1 ± 155.2 mm3 and 204.7 ± 
108.9 mg; and 5-FU + 2-OX, 98.7 ± 64.9 mm3 and 130.3 ± 113.5 mg（Fig.6A, B, C）. 5-FU 
combined with 2-OX significantly inhibited tumor growth in this model, which was 
accompanied by a 53% reduction of Vegf gene expression in tumor tissues removed from mice 
fifteen days after implantation as determined by quantitative RT-PCR analysis（Fig.6D）.  
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Discussion 
 Since the concentration of 2-OX and dioxygen is essential for hydroxylation and 
degradation of HIF-1αprotein, consistent with this report, Jaakkola et al. examined a series of 
2-OX analogs that act as competitive inhibitors of PHDs (26) for their ability to inhibit HIF-PHD 
(21). We also reported that 2-OX treatment of Hep3B cells induced HIF-1αdegradation in vitro 
and reduced the production of VEGF protein（22）. Treatment with 2-OX also restored PHD2 to 
control levels and abolished the nuclear accumulation of HIF-1α（27）. Based on cell culture 
studies, cell-permeating 2-OX derivatives have been proposed as a new therapy to restore 
normal PHD activity and HIF-1αlevels to those of succinate dehydrogenase-suppressed cells
（28）.These in vitro studies indicate that 2-OX induces HIF-1αdegradation and suppresses gene 
expression downstream of HIF-1. However, it was not clear whether 2-OX could be useful for 
suppression of tumor angiogenesis and its growth in animals. Our current study clearly shows 
that 2-OX reduced the HIF-1αprotein level in LLC cells and reduced LLC cell-induced tumor 
angiogenesis in an animal model. 2-OX also reduced tumor growth in a dose-dependent manner. 
   It is widely recognized that targeting tumor endothelial cells is useful for tumor therapy. 
Bevacizmab, a neutralizing antibody against VEGF, has been used for various tumor therapies 
in combination with chemoreagents（25）. In the present study, we evaluated the effect of 2-OX on 
tumor angiogenesis in a DAS model. Addition of 2-OX clearly reduced LLC tumor growth in a 
dose-dependent manner. Furthermore, combining 2-OX and 5-FU revealed more drastic 
anti-tumor activity compared with single injections. It is of note that the Vegf mRNA level was 
reduced in the 2-OX and 5-FU-treated tumor, suggesting that downregulation of Vegf mRNA 
may account, in part, for the reduced tumor growth. Taken together, 2-OX could be an effective 
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chemotherapeutic reagent in combination with 5-FU. 
   Among the three members of the HIF-PHD genes, PHD2 may play a major role in HIF1α 
hydroxylation during hypoxia. However, it is not clear that HIF-1α destabilization by 2-OX is 
mediated by PHD2. Further studies will be required for clarification of the molecular 
mechanism of 2-OX action during the inhibition of tumor angiogenesis and growth. 
   Small chemical molecules that activate or inhibit HIF-PHD are reported. Choi et al. found a 
potent activator of PHD2 called KRH102053 (29). The effects of KRH102053 on controlling HIF 
were studied in cell lines. Under their experimental conditions, KRH102053 decreased the 
protein level of HIF-1αand the mRNA levels of HIF-regulated downstream target genes, such 
as VEGF, aldolase A, enolase 1 and monocarboxylate transporter 4, in cell models. Inhibition of 
HIF–PHD mimics hypoxia, stabilizes HIF, and stimulates Epo gene expression, even under 
normoxic conditions. FibroGen has recently developed a new HIF–PHD inhibitor called 
FG-2216（30）. It completed a phase I study of FG-2216 using 54 healthy subjects in the UK and 
is conducting a phase II study of FG-2216 involving 42 patients with chronic kidney diseases or 
chemically induced anemia in Germany and Poland（30）. Doses of 6 mg/kg of FG-2216 and 
higher cause a dose-dependent elevation of serum EPO, which increased hemoglobin 
concentrations by 1.1 g/dL above the baseline level on day 42 of the study（30）. However, as 
expected, based on the effects of HIF–PHD, there is concern that FG-2216 might increase 
expression of VEGF. The same is equally true of whole body 2-OX administration.  
     2-OX is a metabolite in the TCA cycle and exists in cells at relatively high concentrations. 
Our study clearly showed that various concentrations had no effect on the viability of cultured 
cells but were sufficient to reduce tumor size. Further, 2-OX had no effect on pre-existing 
endothelial cells and had no effect on blood cell count in peripheral blood samples that were 
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obtained from the retro-orbital plexus of mice（data not shown）. Taken together, 2-OX is a 
promising new therapeutic reagent with no apparent side effects for inhibiting tumor 
angiogenesis and tumor size. 
   Hypoxia has been shown to be a very important stimulus for new vessel formation as seen in 
coronary artery disease (31) and diabetic neovascularization (32). HIF-1 is a key transcription 
factor regulating oxygen homeostasis. Arjamaa et al. showed that all oxygen-dependent diseases 
of the retina are regulated by HIF（33）. Thus, it will be very interesting to investigate in future if 
2-OX inhibits other HIF-dependent diseases in animal models. 
 
                            Figure Legends 
 
Fig. 1 
 
Fig. 1. Effect of 2-OX on HIF-1αand HIF-2αmRNA and protein expression in cultured 
LLC. (A) Effect of 2-OX on LLC cell proliferation. LLC cells were incubated with the 
indicated concentrations of 2-OX under normoxic or hypoxic conditions. Cell viability was 
measured by a nonradioactive cell proliferation assay. The number of living cells incubated 
without 2-OX was expressed as 100%. Error bars represent 1 SD (n = 9). Normoxia, 21 % O2; 
Hypoxia, 1 % O2. # indicates significance compared with normoxic control, P < 0.001. ## 
indicates significance compared with normoxic control, P < 0.01. * indicates significance 
compared with hypoxic control, P < 0.001. (B) Effect of 2-OX on HIF-1α and HIF-2α 
mRNA expression. LLC and B16F10 cells were incubated with and without 2-OX under 
normoxic or hypoxic conditions. HIF-1α  and HIF-2α  mRNAs were detected by 
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semi-quantitative RT-PCR.  Normoxia, 21 % O2; Hypoxia, 1 % O2. (C) Effect of 2-OX on 
enhanced expression of HIF-1α protein production in cultured LLC. LLC cells were treated 
with the indicated concentrations of 2-OX under normoxic or hypoxic conditions for 1.5 h. The 
cells were then lysed, and protein was detected with anti-HIF-1α and lamin B antibodies by 
western blotting. The autoradiograph is representative of four different experiments using 
different cell extracts. Numbers below the bands are means ±  1 SD as determined by 
densitometric analysis of the ratio of the bands (HIF-1α/ lamin B) expressed relative to lane 2. 
Triangle indicates HIF-1α. Normoxia, 21 % O2; Hypoxia, 1 % O2. * indicates significance 
compared with control, P < 0.05. **indicates significance compared with control, P < 0.001. 
 
Fig. 2. Effect of 2-OX on Vegf mRNA and protein expression in cultured LLC. (A) Effect of 
2-OX on Vegf mRNA expression. LLC cells were incubated with and without 2-OX under 
normoxic or hypoxic conditions. Vegf mRNA expression was measured by quantitative RT-PCR. 
Three separate experiments（hypoxia exposure time, 1.5h）and six separate experiments（hypoxia 
exposure time, 1.5 h）were performed. Error bars represent 1 SD. Normoxia, 21 % O2; Hypoxia, 
1 % O2. #indicates significance compared with hypoxic control（hypoxia exposure time, 1.5h）, 
P < 0.05. ## indicates significance compared with hypoxic control （hypoxia exposure time, 3h）, 
P < 0.001. * indicates significance compared with hypoxic control （hypoxia exposure time, 3h）, 
P < 0.001. (B) Effect of 2-OX on VEGF protein production from LLC cells. LLC cells were 
incubated with and without 2-OX under normoxic or hypoxic conditions. VEGF protein was 
measured by ELISA. Five separate experiments were performed. Error bars represent 1 SD. 
Normoxia, 21 % O2; Hypoxia, 1 % O2. * indicates significance compared with hypoxic control, 
P < 0.001. ** indicates significance compared with hypoxic control, P < 0.05. 
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Fig. 3. Effect of 2-OX on in vivo blood vessel formation by DAS assay. Chambers filled with 
either PBS alone or PBS plus LLC cells with or without 2-OX were implanted into 
seven-week-old mice. The dorsal skin was peeled off, and blood vessel formation was examined 
under a microscope and photographed. Scale bar, 3 mm. Area of tumor-induced blood vessels 
were analyzed with angiogenesis-measuring software. A representative result from three 
independent experiments with similar results is shown. Four separate experiments were 
performed. Error bars represent 1 SD. * indicates significance compared with LLC only, P < 
0.01. ** indicates significance compared with LLC only, P < 0.05. 
 
Fig.4. Effect of 2-OX on growth of LLC cells in vivo. Cells in PBS were implanted into the 
right flank region of seven-week-old C57BL/6J mice. Daily intraperitoneal injections of 2-OX 
were started the day after implantation. From six to twelve days after implantation, we 
measured tumors with calipers and calculated volumes as (length x width2) x 0.5.（A）Tumor 
volume.（B）Gross appearance of xenografts and excised tumors at day 12. Scale bar, 5mm.（C）
Tumor weight at day 12. A representative result from three independent experiments with 
similar results is shown. Five separate experiments were performed. Error bars represent 1 SD. 
*indicates significance compared with control, P < 0.001. ** indicates significance compared 
with control, P < 0.01. *** indicates significance compared with control, P < 0.025. **** 
indicates significance compared with control, P < 0.05.  
 
Fig.5 Effect of 2-OX on microvessel density in LLC tumors. Cells in PBS were implanted 
into the right flank region of seven-week-old C57BL/6J mice. Daily intraperitoneal injections of 
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2-OX were started the day after implantation. LLC tumors were removed from mice twelve 
days after the implantation for immunohistochemical studies. （A）Immunohistochemical 
studies for CD31 and blood vessel formation was examined under a microscope and 
photographed. Scale bar, 150μm. （B）Area of microvessel density was analyzed with 
angiogenesis-measuring software. A representative result from three independent experiments 
with similar results is shown. Four separate experiments were performed. Error bars represent 1 
SD. *indicates significance compared with control, P < 0.005. (C) Effect of 2-OX on Vegf 
mRNA expression in LLC tumor. Cells in PBS were implanted into the right flank region of 
seven-week-old C57BL/6J mice. Daily intraperitoneal injections of 2-OX were started the day 
after implantation. LLC tumors were removed from mice twelve days after the implantation for 
quantitative RT-PCR. Nine separate experiments were performed. Error bars represent 1 SD. 
Vegf mRNA levels in LLC tumors were quantified by quantitative RT-PCR and normalized to 
the level of Actin mRNA. 
 
Fig.6. Effect of 2-OX and/or 5-FU on growth of LLC cells in vivo. Cells in PBS were 
implanted into the right flank region of seven-week-old C57BL/6J mice. Intraperitoneal 
injections of the indicated cocktails occurred daily beginning on day 7 after implantation. From 
six to fifteen days after implantation, we measured tumors with calipers and calculated volumes 
as (length x width2) x 0.5.（A）Tumor volume. （B）Gross appearance of xenografts and excised 
tumors at day 15. Scale bar, 5mm.（C）Tumor weight at day 15. A representative result from 
three independent experiments with similar results is shown. Five separate experiments were 
performed. Error bars represent 1 SD. *indicates significance compared with control, P < 0.05. 
** indicates significance compared with control, P < 0.01.  (D) Effect of 2-OX in combination 
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with 5-FU on Vegf mRNA expression in vivo. Cells in PBS were implanted into the right flank 
region of seven-week-old C57BL/6J mice. Intraperitoneal injections of the indicated cocktails 
occurred daily beginning at day 7 after implantation. LLC tumors were removed from mice 
fifteen days after implantation for quantitative RT-PCR. Eight separate experiments were 
performed. Error bars represent 1 SD. *indicates significance compared with control, P < 0.01. 
Vegf mRNA levels in LLC tumors were quantified by quantitative RT-PCR and normalized to 
the level of Actin mRNA. 
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